Accelerating Antibiotic Drug Development: FDA Goes Beyond GAIN
This article was originally published in RPM Report
Executive Summary
FDA is sending a message to industry and Congress of its ongoing work to help companies with antibiotic drug development– beyond the requirements of the FDA Safety and Innovation Act.